WA
ARNA

Winfield Associates’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Winfield Associates’s Portfolio ARNA Stock Details ARNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-200
Closed -$9K – 295
2015
Q1 		$9K Hold
200
– – 0.01% 242
2014
Q4 		$7K Hold
200
– – 0.01% 252
2014
Q3 		$8K Hold
200
– – 0.01% 244
2014
Q2 		$11K Hold
200
– – 0.01% 246
2014
Q1 		$13K Hold
200
– – 0.01% 230
2013
Q4 		$12K Buy
+200
New +$10.5K 0.01% 236

Other funds holding ARNA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Winfield Associates's ARNA Position: Q2 2015 in Review

Winfield Associates sold out of Arena Pharmaceuticals Inc (ARNA) in Q2 2015, closing a stake of 200 shares — an estimated $9K sold.

Winfield Associates first reported a position in ARNA in Q4 2013 and held it in 6 quarters. The position peaked at $13K in Q1 2014. 130 funds tracked by Wall St. Rank hold ARNA as of Q2 2015.

  • Winfield Associates reported no remaining Arena Pharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Winfield Associates sold 200 Arena Pharmaceuticals Inc shares in Q2 2015, an estimated $9K.
  • Winfield Associates first reported a position in Arena Pharmaceuticals Inc in Q4 2013 and held it in 6 quarters.
  • Winfield Associates's Arena Pharmaceuticals Inc position peaked at $13K in Q1 2014.
  • 130 funds tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q2 2015.

Based on Winfield Associates's 13F filing for Q2 2015, filed 14 Aug 2015.